查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589791

癲癇藥物市場：按產品類型、分銷管道 - 全球預測 2025-2030

Epilepsy Drug Market by Product Type (First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癲癇藥物市值為45.5億美元，預計到2024年將達到48.7億美元，複合年成長率為7.09%，到2030年將達到73.5億美元。

癲癇藥物市場包括多種用於控制和治療癲癇的藥物，癲癇是一種以反覆發作為特徵的神經系統疾病。這些藥物的需求源於控制癲癇發作、盡量減少副作用和改善癲癇患者生活品質的需要。這些治療劑主要由醫院和診所的醫療保健提供者以及患者本身使用，並構成治療方法的組成部分。藥理學的進步擴大了最終用途的範圍，包括學名藥和特種藥物，以滿足各種個人的需求。影響市場開拓的關鍵因素包括癲癇盛行率的增加、對神經系統疾病的認知不斷提高以及藥物開發和配方的進步。此外，個人化醫療和生技藥品的創新提供了巨大的成長機會。一個值得注意的機會是開發一種療效較高、副作用較少的藥物，以針對對傳統治療有抵抗力的特定類型癲癇。然而，高昂的藥物開發成本、嚴格的監管流程和潛在的副作用等挑戰阻礙了市場的成長。此外，專利到期還會帶來學名藥市場飽和的風險，進而影響盈利。為了應對這些限制，專注於新治療機制的研究並利用個人化治療技術（例如使用人工智慧進行基因組分析和藥物發現）可能非常有利。鑑於市場競爭激烈且監管嚴格，與研究機構的策略聯盟以及使用真實​​世界的藥物功效證據可能會縮短開發時間。投資於醫療保健成本不斷上升、未滿足的醫療需求不斷增加的新興市場也可以提供強勁的成長軌跡。因此，創新和研究的最佳領域是開發治療解決方案，解決未滿足的需求，提高患者的依從性，並與不斷發展的醫療保健政策保持一致，從而支持持續的市場成長。地位。

主要市場統計
基準年[2023] 45.5億美元
預測年份 [2024] 48.7億美元
預測年份 [2030] 73.5億美元
複合年成長率（%） 7.09%

市場動態：快速發展的癲癇藥物市場的關鍵市場洞察

供需的動態交互作用正在改變癲癇藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癲癇患者增加
    • 神經系統疾病、產傷及交通傷害的發生率增加
    • 政府加大投入與支持
  • 市場限制因素
    • 缺乏基礎設施和癲癇治療
  • 市場機會
    • 抗驚厥藥物的監管核准增加
    • 聯合研究和產品發布活動的滲透
  • 市場挑戰
    • 與藥物相關的副作用

波特五力：駕馭癲癇藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癲癇藥物市場的影響

外部宏觀環境因素在塑造癲癇藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癲癇藥物市場的競爭狀況

對癲癇藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癲癇藥物市場供應商的績效評估

FPNV定位矩陣是評估癲癇藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪癲癇藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，癲癇藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癲癇盛行率增加
      • 神經系統疾病、分娩相關傷害和交通事故的發生率增加
      • 政府加大投入與支持
    • 抑制因素
      • 缺乏癲癇基礎設施和治療
    • 機會
      • 抗驚厥藥物的監管核准增加
      • 增加協作和產品發布活動
    • 任務
      • 與藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癲癇藥物市場：依產品類型

  • 第一代醫學
    • 乙磺醯亞胺
    • 奧卡西平
    • 苯妥英
  • 第二代醫學
    • 非氨酯
    • 拉莫三嗪
    • 托吡酯
  • 第三代醫學
    • 醋酸艾斯利卡西平
    • 拉科醯胺
    • 拉非醯胺

第7章 癲癇藥物市場：依通路

  • 醫院藥房
  • 藥局

第8章美洲癲癇藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區癲癇藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的癲癇藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Densa Pharmaceuticals Pvt. Ltd.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Micro Labs Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Psychotropics India Ltd.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • UCB SA
Product Code: MRR-4348D129FAC3

The Epilepsy Drug Market was valued at USD 4.55 billion in 2023, expected to reach USD 4.87 billion in 2024, and is projected to grow at a CAGR of 7.09%, to USD 7.35 billion by 2030.

The epilepsy drug market encompasses a diverse range of medications designed for the management and treatment of epilepsy, a neurological disorder characterized by recurrent seizures. The necessity for these drugs arises from the need to control seizures, minimize side effects, and improve quality of life for epilepsy patients. These medications are primarily utilized by healthcare providers in hospitals, clinics, and by patients themselves, forming an integral part of treatment regimens. Advances in pharmacology have broadened the end-use scope to encompass both generic and specialty drugs catering to various individual needs. Key factors influencing market growth include increased prevalence of epilepsy, heightened awareness about neurological disorders, and advancements in drug development and formulation. Additionally, innovation in personalized medicine and biologics presents significant growth opportunities. One notable opportunity is the development of drugs with improved efficacy and reduced side effects, targeting specific types of epilepsy that are resistant to conventional treatments. However, challenges such as high drug development costs, stringent regulatory processes, and potential side effects hinder market growth. Moreover, patent expirations pose risks of market saturation with generics, impacting profitability. To counter these limitations, focusing on research for new treatment mechanisms and leveraging technology for personalized treatments, such as genomics and AI-driven drug discovery, could be highly advantageous. Given the nature of the market being highly competitive and heavily regulated, strategic alliances with research institutions and leveraging real-world evidence for drug efficacy could accelerate development timelines. Investments in emerging markets with rising healthcare expenditures and unmet medical needs could also provide substantial growth trajectories. Thus, the best areas of innovation and research involve developing therapeutic solutions that address unmet needs, improve patient adherence, and align with evolving healthcare policies, thereby ensuring sustained market growth and leadership.

KEY MARKET STATISTICS
Base Year [2023] USD 4.55 billion
Estimated Year [2024] USD 4.87 billion
Forecast Year [2030] USD 7.35 billion
CAGR (%) 7.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Epilepsy Drug Market

The Epilepsy Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalences of epilepsy
    • Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
    • Rising investment and support from the government
  • Market Restraints
    • Lack of infrastructure and scarcity of treatment for epilepsy
  • Market Opportunities
    • Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • Penetration of collaboration and product launch activities
  • Market Challenges
    • Side effects associated with the drugs

Porter's Five Forces: A Strategic Tool for Navigating the Epilepsy Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Epilepsy Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Epilepsy Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Epilepsy Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Epilepsy Drug Market

A detailed market share analysis in the Epilepsy Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Epilepsy Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Epilepsy Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Epilepsy Drug Market

A strategic analysis of the Epilepsy Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Epilepsy Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Densa Pharmaceuticals Pvt. Ltd., Eisai Co., Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Micro Labs Ltd., Novartis International AG, Pfizer Inc., Psychotropics India Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Epilepsy Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs. The First-Generation Drugs is further studied across Ethosuximide, Oxcarbazepine, and Phenytoin. The Second-Generation Drugs is further studied across Felbamate, Lamotrigine, and Topiramate. The Third-Generation Drugs is further studied across Eslicarbazepine Acetate, Lacosamide, and Ralfinamide.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy and Pharmacy Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalences of epilepsy
      • 5.1.1.2. Rising incidence of neurological disorders, birth-related injuries, and traffic injuries
      • 5.1.1.3. Rising investment and support from the government
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of infrastructure and scarcity of treatment for epilepsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Penetration of collaboration and product launch activities
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Epilepsy Drug Market, by Product Type

  • 6.1. Introduction
  • 6.2. First-Generation Drugs
    • 6.2.1. Ethosuximide
    • 6.2.2. Oxcarbazepine
    • 6.2.3. Phenytoin
  • 6.3. Second-Generation Drugs
    • 6.3.1. Felbamate
    • 6.3.2. Lamotrigine
    • 6.3.3. Topiramate
  • 6.4. Third-Generation Drugs
    • 6.4.1. Eslicarbazepine Acetate
    • 6.4.2. Lacosamide
    • 6.4.3. Ralfinamide

7. Epilepsy Drug Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Pharmacy Stores

8. Americas Epilepsy Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Epilepsy Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Epilepsy Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Densa Pharmaceuticals Pvt. Ltd.
  • 3. Eisai Co., Ltd.
  • 4. GlaxoSmithKline PLC
  • 5. Johnson & Johnson Services, Inc.
  • 6. Micro Labs Ltd.
  • 7. Novartis International AG
  • 8. Pfizer Inc.
  • 9. Psychotropics India Ltd.
  • 10. Sanofi S.A.
  • 11. Sun Pharmaceutical Industries Ltd.
  • 12. Sunovion Pharmaceuticals, Inc.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Torrent Pharmaceuticals Ltd.
  • 15. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. EPILEPSY DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. EPILEPSY DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EPILEPSY DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EPILEPSY DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EPILEPSY DRUG MARKET SIZE, BY OXCARBAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHENYTOIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EPILEPSY DRUG MARKET SIZE, BY FELBAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EPILEPSY DRUG MARKET SIZE, BY ESLICARBAZEPINE ACETATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EPILEPSY DRUG MARKET SIZE, BY LACOSAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EPILEPSY DRUG MARKET SIZE, BY RALFINAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY FIRST-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY SECOND-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY THIRD-GENERATION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2023